KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients. External Web Site Icon Garzón Mónica et al. Translational lung cancer research 2016 Oct 5(5) 511-516

https://phgkb.cdc.gov/GAPPKB/phgHome.do

From From Genomics & Health Impact Scan Database

This database includes published scientific literature on evidence-based translation of genomic discoveries into improved health care and disease prevention that have a potential impact on population health.

---

• KRAS mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.  
  Garzón Mónica et al. Translational lung cancer research 2016 Oct 5(5) 511-516
• Technological considerations for genome-guided diagnosis and management of cancer.  
  Lennon Niall J et al. Genome medicine 2016 Oct 8(1) 112
• Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.  
  Takai Erina et al. Advances in experimental medicine and biology 2016 92413-17
• The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus.  
  Eralp Yesim et al. Translational oncogenomics 2016 8(Suppl 1) 1-7
• Blood Test for Genetic Changes in Tumors Shows Promise as Alternative to Tumor Biopsy  
  NCI, June 14, 2016

more